NCT06014164

Brief Summary

This study is set up to better understand the current use of psychedelics in France in the general population. The present focus on individuals who have used any type of psychedelic drug in order to suppress or alleviate a psychiatric symptom in the context of a diagnosed pathology. The data are collected during a semi-structured interview and then studied in a thematic analysis.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
25

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Nov 2023

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 22, 2023

Completed
6 days until next milestone

First Posted

Study publicly available on registry

August 28, 2023

Completed
3 months until next milestone

Study Start

First participant enrolled

November 30, 2023

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 10, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 10, 2025

Completed
Last Updated

November 8, 2023

Status Verified

November 1, 2023

Enrollment Period

1.3 years

First QC Date

August 22, 2023

Last Update Submit

November 7, 2023

Conditions

Psychiatric Disorder

Keywords

Psychiatric disorderPsychedelics

Outcome Measures

Primary Outcomes (1)

  • Experiences of people using psychedelic substances

    Experiences description of people with psychiatric disorders who use psychedelic substances for therapeutic purposes will be assessed by interview

    Baseline

Secondary Outcomes (1)

  • Profile of people using psychedelic substances

    Baseline

Study Arms (1)

Patients using psychedelic substances

Adult patients self-administering psychedelic substances in psychiatric disorders

Diagnostic Test: Interview

Interventions

InterviewDIAGNOSTIC_TEST

An interview will be conducted to describe the experiences of people with psychiatric disorders who use psychedelic substances for therapeutic purposes

Patients using psychedelic substances

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adults patients self-administering psychodelic substances for therapeutic purposes

You may qualify if:

  • Patients diagnosed with a psychiatric disorder by a psychiatrist or general practitioner
  • Patients used psychedelic or related substances in order to treat psychiatric symptoms
  • Patients have given their oral non-opposition
  • Patients affiliated to a social security scheme

You may not qualify if:

  • Patients who don't speak or understand French
  • Patients under protection, guardianship or curators

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Mental Disorders

Study Officials

  • Antoine YRONDI, MD

    University Hospital, Toulouse

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Antoine YRONDI, MD

CONTACT

0561778603yrondi.a@chu-toulouse.fr

Paul ROCHEFORT

CONTACT

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 22, 2023

First Posted

August 28, 2023

Study Start

November 30, 2023

Primary Completion

March 10, 2025

Study Completion

March 10, 2025

Last Updated

November 8, 2023

Record last verified: 2023-11